Omnicell, Inc.
Rank #268ValueOMCL · Nasdaq · Healthcare
Omnicell, Inc. (OMCL) — Rank #268 by gross profitability (GP/assets 0.25) · ROE 0.2% · Piotroski F-Score N/A.
As-of 2026-09-28 · CIK 0000926326 · all metrics point-in-time as of the filing date.
About
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Show moreShow less
It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc.
was incorporated in 1992 and is headquartered in Fort Worth, Texas.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- omnicell.com
Company Snapshot
P/E and dividend yield are the primary valuation lenses for mature businesses.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
3,485
Industry
Health Information Services
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
Disclosure regression check
A previously-disclosed line item is no longer reported. Worth checking the filing for why.
Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).
Profitability
Gross profitability (GP / assets)
0.25
Primary signal (Novy-Marx).
58th pctl of 27 SIC 35 peers
Return on equity
0.2%
Gross margin
42.5%
46th pctl of 27 SIC 35 peers
Revenue growth (YoY)
6.5%
RPO growth (YoY)
-1.1%
Remaining performance obligations growth — RPO > revenue = forward demand building.
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
-2.9%
Revenue CAGR (5Y)
5.8%
Earnings CAGR (3Y)
-28.6%
FCF CAGR (3Y)
42.2%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.55
81st pctl of 27 SIC 35 peers (best = lowest)
Current ratio
1.64×
27th pctl of 27 SIC 35 peers
Quick ratio
1.16×
Net cash
$292.17M
Cash & equivalents minus total debt.
Recession resistance
Revenue through recessions
Worst single-year YoY revenue decline, 17 years of history
Cash-flow health
Free cash flow
$86.89M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
41.34
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
3.8%
Stock-based comp intensity.
Piotroski F-Score
F-Score
N/A
Only 8/9 components determinable.